ArticleFrontiers in oncology2023
Surgical management of giant pituitary adenomas: institutional experience and clinical outcomes of 94 patients.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Surgically treated giant pituitary neuroendocrine tumors: systematic review and meta-analysis with institutional cohort.Neurosurgical review · 2026Pooled it
- Pituitary adenomas associated with hydrocephalus: clinical characteristics, risk stratification, and clinical management.Journal of neuro-oncology · 2026Article
- Giant pituitary adenomas: an institutional experience with 289 surgically treated patients.Acta neurochirurgica · 2026Article
- Early rupture of an anterior communicating artery pseudoaneurysm after transsphenoidal surgery: A case report and clinical implications.Surgical neurology international · 2026Article
- Comparison of complete resection rate and endocrine function improvement between neuronavigation-assisted neuroendoscopic transnasal transsphenoidal approach and microscopic transcranial approach for giant pituitary adenoma.American journal of cancer research · 2026Article
- Endoscopic endonasal resection of giant pituitary adenomas - case series from the referral pituitary center.Pituitary · 2025Article
- Endoscopic endonasal intradural pituitary transposition for resecting retroinfundibular lesions: technique notes and a single institute experience.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Giant (with a diameter of at least 40 mm and a volume of at least 10 cm Methods: A retrospective review was conducted on the clinical records of 94 patients diagnosed with GPAs who had undergone surgical resection from 2014 to 2022. An analysis was conducted on the outcomes of the surgical and clinical procedures. Results: In this group, the average size of the tumor before surgery was 44.6 ± 5.6 mm (range, 40-73 mm), and the volume was 25. 5± 16.6 cm Conclusion: ETS remains the optimal surgical option for most GPAs and generally offers safe and efficient tumor resection. However, a combined approach with TCS remains a requirement in cases that are not suitable for treatment with a single ETS. To achieve optimal tumor removal and minimize the occurrence of surgical complications, a flexible combination of ETS and TCS is recommended based on the characteristics of the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.